Tazocin

Tazocin (piperacillin/tazobactam) combines piperacillin, an extended-spectrum ureidopenicillin that inhibits bacterial cell wall synthesis via PBP binding with broad gram-negative coverage, with tazobactam, a penicillanic acid sulfone beta-lactamase inhibitor that protects piperacillin from enzymatic degradation by Class A beta-lactamases. This combination restores activity against beta-lactamase-producing organisms including many Enterobacteriaceae and anaerobes, making it a workhorse empiric antibiotic for hospital-acquired infections.

Adult

Serious infections: 4.5 g (piperacillin 4g/tazobactam 500mg) IV every 8 hours; increase to every 6 hours for severe infections. Neutropenic patients: 4.5 g every 6 hours.